Literature DB >> 25200099

Difference in performance of fecal immunochemical tests with the same hemoglobin cutoff concentration in a nationwide colorectal cancer screening program.

Tsung-Hsien Chiang1, Shu-Lin Chuang2, Sam Li-Sheng Chen3, Han-Mo Chiu4, Amy Ming-Fang Yen3, Sherry Yueh-Hsia Chiu5, Jean Ching-Yuan Fann6, Chu-Kuang Chou7, Yi-Chia Lee8, Ming-Shiang Wu9, Hsiu-Hsi Chen2.   

Abstract

BACKGROUND & AIMS: We investigated whether 2 quantitative fecal immunochemical tests (FITs) with the same cutoff concentration of fecal hemoglobin perform equivalently in identifying patients with colorectal cancer (CRC).
METHODS: A total of 956,005 Taiwanese subjects, 50 to 69 years old, participated in a nationwide CRC screening program to compare results from 2 FITs; 78% were tested using the OC-Sensor (n = 747,076; Eiken Chemical Co, Tokyo, Japan) and 22% were tested using the HM-Jack (n = 208,929; Kyowa Medex Co Ltd, Tokyo, Japan), from 2004 through 2009. The cutoff concentration for a positive finding was 20 μg hemoglobin/g feces, based on a standardized reporting unit system. The tests were compared using short-term and long-term indicators of performance.
RESULTS: The OC-Sensor test detected CRC in 0.21% of patients, with a positive predictive value of 6.8%. The HM-Jack test detected CRC in 0.17% of patients, with a positive predictive value of 5.2%. The rate of interval cancer rate was 30.7/100,000 person-years among subjects receiving the OC-Sensor test and 40.6/100,000 person-years among those receiving the HM-Jack test; there was significant difference in test sensitivity (80% vs 68%, P = .005) that was related to the detectability of proximal CRC. After adjusting for differences in city/county, age, sex, ambient temperature, and colonoscopy quality, significant differences were observed between the tests in the positive predictive value for cancer detection (adjusted relative risk = 1.29; 95% confidence interval, 1.14-1.46) and the rates of interval cancer (0.75; 95% confidence interval, 0.62-0.92). Although each test was estimated to reduce CRC mortality by approximately 10%, no significant difference in mortality was observed when the 2 groups were compared.
CONCLUSIONS: Different brands of quantitative FITs, even with the same cutoff hemoglobin concentration, perform differently in mass screening. Population-level data should be gathered to verify the credibility of quantitative laboratory findings.
Copyright © 2014 AGA Institute. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Colorectal Cancer; Interval Cancer; Population Screening; Screening Test Sensitivity

Mesh:

Substances:

Year:  2014        PMID: 25200099     DOI: 10.1053/j.gastro.2014.08.043

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  34 in total

1.  Participant-Related Risk Factors for False-Positive and False-Negative Fecal Immunochemical Tests in Colorectal Cancer Screening: Systematic Review and Meta-Analysis.

Authors:  Clasine M de Klerk; Lisanne M Vendrig; Patrick M Bossuyt; Evelien Dekker
Journal:  Am J Gastroenterol       Date:  2018-08-29       Impact factor: 10.864

2.  Making FIT Count: Maximizing Appropriate Use of the Fecal Immunochemical Test for Colorectal Cancer Screening Programs.

Authors:  Vivy T Cusumano; Folasade P May
Journal:  J Gen Intern Med       Date:  2020-03-03       Impact factor: 5.128

3.  Detection of Advanced Neoplasia with FIT Versus Flexible Sigmoidoscopy Versus Colonoscopy: More Is More.

Authors:  Robert E Schoen; Jorge D Machicado
Journal:  Dig Dis Sci       Date:  2015-05       Impact factor: 3.199

Review 4.  Guaiac-based faecal occult blood tests versus faecal immunochemical tests for colorectal cancer screening in average-risk individuals.

Authors:  Esmée J Grobbee; Pieter Ha Wisse; Eline H Schreuders; Aafke van Roon; Leonie van Dam; Ann G Zauber; Iris Lansdorp-Vogelaar; Wichor Bramer; Sarah Berhane; Jonathan J Deeks; Ewout W Steyerberg; Monique E van Leerdam; Manon Cw Spaander; Ernst J Kuipers
Journal:  Cochrane Database Syst Rev       Date:  2022-06-06

Review 5.  Recommendations on Fecal Immunochemical Testing to Screen for Colorectal Neoplasia: A Consensus Statement by the US Multi-Society Task Force on Colorectal Cancer.

Authors:  Douglas J Robertson; Jeffrey K Lee; C Richard Boland; Jason A Dominitz; Francis M Giardiello; David A Johnson; Tonya Kaltenbach; David Lieberman; Theodore R Levin; Douglas K Rex
Journal:  Am J Gastroenterol       Date:  2016-10-18       Impact factor: 10.864

6.  Proton-pump inhibitors are associated with a high false-positivity rate in faecal immunochemical testing.

Authors:  Gemma Ibáñez-Sanz; Núria Milà; Luisa C de la Peña-Negro; Montse Garcia; Carmen Vidal; Lorena Rodríguez-Alonso; Gemma Binefa; Francisco Rodríguez-Moranta; Victor Moreno
Journal:  J Gastroenterol       Date:  2020-11-07       Impact factor: 7.527

7.  Influence of Varying Quantitative Fecal Immunochemical Test Positivity Thresholds on Colorectal Cancer Detection: A Community-Based Cohort Study.

Authors:  Kevin Selby; Christopher D Jensen; Jeffrey K Lee; Chyke A Doubeni; Joanne E Schottinger; Wei K Zhao; Jessica Chubak; Ethan Halm; Nirupa R Ghai; Richard Contreras; Celette Skinner; Aruna Kamineni; Theodore R Levin; Douglas A Corley
Journal:  Ann Intern Med       Date:  2018-09-18       Impact factor: 25.391

8.  A Comparison of Fecal Immunochemical and High-Sensitivity Guaiac Tests for Colorectal Cancer Screening.

Authors:  Jean A Shapiro; Janet K Bobo; Timothy R Church; Douglas K Rex; Gary Chovnick; Trevor D Thompson; Ann G Zauber; David Lieberman; Theodore R Levin; Djenaba A Joseph; Marion R Nadel
Journal:  Am J Gastroenterol       Date:  2017-10-10       Impact factor: 10.864

9.  The sensitivity, specificity, predictive values, and likelihood ratios of fecal occult blood test for the detection of colorectal cancer in hospital settings.

Authors:  Salah H Elsafi; Norah I Alqahtani; Nawaf Y Zakary; Eidan M Al Zahrani
Journal:  Clin Exp Gastroenterol       Date:  2015-09-09

10.  Timing and Risk Factors for a Positive Fecal Immunochemical Test in Subsequent Screening for Colorectal Neoplasms.

Authors:  Tsung-Hsien Chiang; Yi-Chia Lee; Wan-Chung Liao; Jui-Hung Chung; Han-Mo Chiu; Chia-Hung Tu; Su-Chiu Chen; Ming-Shiang Wu
Journal:  PLoS One       Date:  2015-09-02       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.